Stanford study identifies six depression biotypes for personalized treatment

FHS
June 17, 2024
1:51 pm

In the not-too-distant future, a screening assessment for depression could include a quick brain scan to identify the best treatment.

New combination treatment offers hope for older patients with mantle cell lymphoma

The phase 2 trial PrE0405 met its primary endpoint, achieving a complete response (CR) rate of 85% in 33 patients over the age of 60

December 12, 2023

GE HealthCare, Mass General Brigham Integrate AI Medical Imaging Foundation Models

What You Should Know: – GE HealthCare and Mass General Brigham, longstanding partners in artificial intelligence (AI) research, have announced a new initiative focused on

March 12, 2024

Cybin Provides Corporate Update and Highlights Key Upcoming Milestones Across its Development Pipeline | Psychedelic Invest

–Company to host conference call to discuss positive Phase 2 CYB003 interim results today, November 1, 2023 at 11:00 a.m. ET – – Complete Phase

November 2, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.